Anti-cancer drugs: Molecular mechanisms of action

被引:19
|
作者
Isoldi, MC
Visconti, MA
Castrucci, AMD
机构
[1] Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA
[2] Univ Sao Paulo, Inst Biociencias, Dept Fisiol, BR-05508900 Sao Paulo, Brazil
关键词
cell signaling; cancer; mechanisms of action; Ras protein; P53;
D O I
10.2174/1389557054368781
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Genetic alterations are responsible for all cancers. These mutations produce, in turn, alterations in key proteins of certain signaling pathways. Amongst the best known and studied alterations related to malignant transformations are those which occur in Ras protein and p53. In most cases mutations in Ras and p53 lead to the appearance of practically most malignant transformations. Mutated Ras genes exist in approximately 20 to 30% of all human cancers. Ras proteins are switches that regulate diverse functions such as cell proliferation, differentiation and apoptosis. Normal p53 expression, also known as the "genome guardian", is a key molecule for suppressing cell proliferation. The great importance of these proteins rests on their intimacy with the events leading to cell proliferation or death. The comprehension of the extent of transformation on Ras and p53, and of the diverse biochemical pathways of intracellular signaling, activated by them, is of extreme importance for the understanding of malignant transformation, as well as its control, through the creation, for example, of new drugs which contribute to the elimination of these cells. To clarify the consequences originated by transformed Ras, p53 and their biochemical interlinks in the different intracellular pathways, besides the possible intervening points and pharmacological controls presently used in combating cancer, are the aims of this review.
引用
收藏
页码:685 / 695
页数:11
相关论文
共 50 条
  • [1] POSSIBLE MECHANISMS OF ACTION OF PLATINUM ANTI-CANCER DRUGS
    ROSENBERG, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 330 - 330
  • [2] Potential Mechanisms of Action of Bisphosphonates as Anti-Cancer Drugs
    Rogers, M. J.
    Roelofs, A. J.
    BONE, 2010, 47 : S280 - S280
  • [3] Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs
    Kim, Hyun-Jung
    Bae, Suk-Chul
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2011, 3 (02): : 166 - 179
  • [4] Molecular Mechanisms of Anti-cancer Action of Garlic Compounds in Neuroblastoma
    Karmakar, Surajit
    Choudhury, Subhasree Roy
    Banik, Naren L.
    Ray, Swapan K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2011, 11 (04) : 398 - 407
  • [5] Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action
    Quayle, Lewis A.
    Pereira, Maria G.
    Scheper, Gerjan
    Wiltshire, Tammy
    Peake, Ria E.
    Hussain, Issam
    Rea, Carol A.
    Bates, Timothy E.
    ONCOTARGET, 2017, 8 (51) : 88670 - 88688
  • [6] Molecular mechanisms of action of Vernonia Amygdalina as anti-cancer in the management of breast cancer
    Yedjou, Clement G.
    Tchounwou, Paul B.
    Izevbigie, Ernest B.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [7] Editorial: New mechanisms for anti-cancer drugs
    Shahid, Ayaz
    Prakash, Ajit
    Mustafa, Saad
    Prabhakar, Pranav Kumar
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] Mechanisms of anti-cancer action and pharmacology of clofarabine
    Zhenchuk, Anna
    Lotfi, Koroush
    Juliusson, Gunnar
    Albertioni, Freidoun
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (11) : 1351 - 1359
  • [9] Retinoids as anti-cancer agents and their mechanisms of action
    Jin, Ying
    Teh, Soek Sin
    Lau, Harrison Lik Nang
    Xiao, Jianbo
    Mah, Siau Hui
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (03): : 938 - 960
  • [10] Emerging anti-cancer molecular mechanisms of aminobisphosphonates
    Caraglia, M
    Santini, D
    Marra, M
    Vincenzi, B
    Tonini, G
    Budillon, A
    ENDOCRINE-RELATED CANCER, 2006, 13 (01) : 7 - 26